Market closed
Replimune/$REPL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Ticker
$REPL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
331
Website
Replimune Metrics
BasicAdvanced
$952M
Market cap
-
P/E ratio
-$3.20
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$952M
Beta
1.19
52-week high
$14.00
52-week low
$4.92
Average daily volume
931K
Financial strength
Current ratio
10.108
Quick ratio
9.913
Long term debt to equity
18.919
Total debt to equity
17.81
Interest coverage (TTM)
-30.90%
Management effectiveness
Return on assets (TTM)
-27.07%
Return on equity (TTM)
-50.32%
Valuation
Price to book
2.27
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-4.468
Growth
Earnings per share change (TTM)
3.49%
3-year earnings per share growth (CAGR)
17.95%
What the Analysts think about Replimune
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Replimune Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Replimune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Replimune News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Replimune stock?
Replimune (REPL) has a market cap of $952M as of December 13, 2024.
What is the P/E ratio for Replimune stock?
The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of December 13, 2024.
Does Replimune stock pay dividends?
No, Replimune (REPL) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Replimune dividend payment date?
Replimune (REPL) stock does not pay dividends to its shareholders.
What is the beta indicator for Replimune?
Replimune (REPL) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.